Literature DB >> 15615528

Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors.

Francesco Leonetti1, Angelo Favia, Angela Rao, Rosaria Aliano, Anja Paluszcak, Rolf W Hartmann, Angelo Carotti.   

Abstract

The design, synthesis, and biological evaluation of a series of new aromatase inhibitors bearing an imidazole or triazole ring linked to a fluorene (A), indenodiazine (B), or coumarin scaffold (C) are reported. Properly substituted coumarin derivatives displayed the highest aromatase inhibitory potency and selectivity over 17-alpha-hydroxylase/17-20 lyase. The modeling of the aromatase inhibition data by Comparative Molecular Field Analysis (CoMFA/GOLPE 3D QSAR approach) led to the development of a PLS model with good fitting and predictive powers (n = 22, ONC = 3, r(2) = 0.949, s = 0.216, and q(2) = 0.715). The relationship between aromatase inhibition and the steric and electrostatic fields generated by the examined azole inhibitors enables a clear understanding of the nature and spatial location of the main interactions modulating the aromatase inhibitory potency.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15615528     DOI: 10.1021/jm049535j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  14 in total

1.  Development of a new class of aromatase inhibitors: design, synthesis and inhibitory activity of 3-phenylchroman-4-one (isoflavanone) derivatives.

Authors:  Kevin Bonfield; Erica Amato; Tony Bankemper; Hannah Agard; Jeffrey Steller; James M Keeler; David Roy; Adam McCallum; Stefan Paula; Lili Ma
Journal:  Bioorg Med Chem       Date:  2012-02-27       Impact factor: 3.641

2.  Combinatorial Synthesis of Structurally Diverse Triazole-Bridged Flavonoid Dimers and Trimers.

Authors:  Tze Han Sum; Tze Jing Sum; Warren R J D Galloway; Súil Collins; David G Twigg; Florian Hollfelder; David R Spring
Journal:  Molecules       Date:  2016-09-16       Impact factor: 4.411

3.  First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Carsten A Vock; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2010-10-22       Impact factor: 4.345

4.  Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.

Authors:  Ulrike E Hille; Christina Zimmer; Jörg Haupenthal; Rolf W Hartmann
Journal:  ACS Med Chem Lett       Date:  2011-06-03       Impact factor: 4.345

5.  Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.

Authors:  Bin Sun; Juma Hoshino; Katie Jermihov; Laura Marler; John M Pezzuto; Andrew D Mesecar; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2010-05-24       Impact factor: 3.641

Review 6.  A review of coumarin derivatives in pharmacotherapy of breast cancer.

Authors:  Musiliyu A Musa; John S Cooperwood; M Omar F Khan
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

7.  Selective inhibition of aromatase by a dihydroisocoumarin from Xyris pterygoblephara.

Authors:  Denise C Endringer; Keller G Guimarães; Tamara P Kondratyuk; John M Pezzuto; Fernão C Braga
Journal:  J Nat Prod       Date:  2008-05-08       Impact factor: 4.050

8.  Palladium-catalyzed substitution of (coumarinyl)methyl acetates with C-, N-, and S-nucleophiles.

Authors:  Kalicharan Chattopadhyay; Erik Fenster; Alexander J Grenning; Jon A Tunge
Journal:  Beilstein J Org Chem       Date:  2012-07-27       Impact factor: 2.883

9.  Structural basis for species specific inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1): computational study and biological validation.

Authors:  Tobias Klein; Claudia Henn; Matthias Negri; Martin Frotscher
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

10.  Synthesis, molecular modeling and anticancer activity of new coumarin containing compounds.

Authors:  Shaimaa A Morsy; Abdelbasset A Farahat; Magda N A Nasr; Atif S Tantawy
Journal:  Saudi Pharm J       Date:  2017-02-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.